Focus On Sites

By working with a range of capable sites, we can reach at-risk populations, bring interventions to those who need it most and address public health issues around the globe.

WE HAVE RELATIONSHIPS WITH SITES WORLDWIDE

Our database of research-ready sites includes approximately 2,500 sites worldwide, with experience spanning all clinical trial phases, infectious and non-communicable diseases as well as pediatric and adult populations.

Are you a site interested in being considered for future studies with FHI Clinical?

Complete the form, and we will contact you to arrange a formal introduction with the FHI Clinical team for further evaluation of your site.

WE PARTNER WITH SITES

Our relationships with sites are built on our shared investment in their sustainability, helping sites develop and maintain research capacity to be able to address public health issues around the globe.
Consistent site activity through additional research opportunities
Additional financial support
Increased independence and sustainability

SITE AND INVESTIGATOR SPOTLIGHT

Each quarter, we shine the light on one of the investigators in our database as well as his or her site(s) and the research priorities in the country.

The current Site and Investigator Spotlight introduces Nsengi Ntamabyaliro, MD, MSc, from the Unit of Clinical Pharmacology and Pharmacovigilance (UPC-PV), University of Kinshasa, in Kinshasa, Democratic Republic of the Congo (DRC). FHI Clinical has worked with Dr. Ntamabyaliro on Phase 3 and 4 trials since 2007, at which time there was a focus on research capacity development in the DRC. Based on this history, FHI Clinical and Dr. Ntamabyaliro are currently collaborating with the UPC-PV on vaccine clinical trials and are working to identify opportunities to keep the research team active at the UPC-PV and the Kinshasa School of Public Health to sustain their research capacity.

About Dr. Ntamabyaliro

Nsengi Ntamabyaliro is a medical doctor who specialized in pharmacoepidemiology and pharmacovigilance. Since 2007 and following his clinical practice in surgery and internal medicine, Dr. Ntamabyaliro has been involved in different roles in many clinical trials: supervisor, site coordinator, co-investigator and principal investigator. His research has focused primarily on malaria but has also included trypanosomiasis, monkeypox and Ebola. Dr. Ntamabyaliro worked as a member of the pharmacovigilance team during the study of EBANGA™, one of the two drugs currently approved by the FDA for the management of Ebola virus disease.

Our relationship with Dr. Ntamabyaliro

FHI Clinical has worked with Dr. Ntamabyaliro on Phase 3 and 4 trials since 2007, at which time there was a focus on research capacity development in the DRC. Based on this history, FHI Clinical and Dr. Ntamabyaliro are currently collaborating with the UPC-PV on vaccine clinical trials and are working to identify opportunities to keep the research team active at the UPC-PV and the Kinshasa School of Public Health to sustain their research capacity.